Denali Therapeutics (DNLI)
(Real Time Quote from BATS)
$23.76 USD
+0.23 (0.98%)
Updated Jul 23, 2024 10:40 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Denali Therapeutics Inc. [DNLI]
Reports for Purchase
Showing records 1 - 20 ( 191 total )
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Donanemab Nears Approval - Implications for the Next Generation AD Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
We Believe DNL310 Can Achieve Accelerated Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
An In-Line Update As We Await Further Clarity on DNL310 [1Q24 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Live From AD/PD Lisbon 2024-Microglia Plays a Crucial Role in Amyloid Cascade
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Live from AD/PD 2024 Lisbon-Mechanistic Insights on ARIA Exploring the Role of Classical Complement Pathway Activation
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Secret to Being a Centenarian Without Dementia Lies with the Lysosomes - Live from AD/PD 2024 Lisbon
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
DNL310 and DNL126?s Future Success Unlocks ETV?s Potential for Lysosomal Storage Diseases; Reiterate Buy; PT Down to $95
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Denali Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
With A Bolstered Balance Sheet, DNLI On The Hunt For DNL310 Regulatory Path
Provider: Wedbush Securities Inc.
Analyst: CHICO L